Filing Details

Accession Number:
0001127602-14-006501
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-14 16:42:13
Reporting Period:
2014-02-12
Filing Date:
2014-02-14
Accepted Time:
2014-02-14 16:42:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875045 Biogen Idec Inc. BIIB Biological Products, (No Disgnostic Substances) (2836) 330112644
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1577061 Alfred Sandrock Biogen Idec Inc.
225 Binney Street
Cambridge MA 02142
Grp Svp, Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-02-12 792 $0.00 14,459 No 4 M Direct
Common Stock Disposition 2014-02-12 367 $323.04 14,092 No 4 F Direct
Common Stock Acquisiton 2014-02-12 7,740 $0.00 21,832 No 4 A Direct
Common Stock Disposition 2014-02-13 425 $316.42 21,407 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2014-02-12 792 $0.00 792 $0.00
Common Stock Restricted Stock Unit Acquisiton 2014-02-12 4,000 $0.00 4,000 $0.00
Common Stock Restricted Stock Unit Acquisiton 2014-02-12 13,340 $0.00 13,340 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,381 2017-02-12 No 4 M Direct
4,000 2017-02-12 No 4 A Direct
13,340 2019-02-12 No 4 A Direct
Footnotes
  1. Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
  2. Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
  3. This represents the weighted average price for shares sold at a range between $316.01 (low) and $316.81 (high).
  4. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).
  5. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
  6. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest each year for four years, beginning two years from the date of grant. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).